-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Photo Source: ASCO Summary Collection Research Data to be published at ASCO Is a Ib/II study for Paiamply (200 mg Q3W) in conjunction with hydrochloride anrotini 8 mg, once daily, for 2 consecutive weeks for 1 week (n s 31).
tumor mitigation assessment uses version 1.1 of the solid tumor efficacy assessment criteria.
Clinical Research Data (as of January 14, 2020): Clinical efficacy: 31 patients administered in the group at the end of the data deadline, with a median follow-up time of 7.0 months, median to disease progression time of 8.8 months, 6 months without disease The progress rate was 59.8% (95% confidence interval: 35.1%, 77.6%), the median total lifetime has not yet been reached, and the total survival rate for 6 months was 91.6% (95% confidence interval: 69.9%, 97.9%).
Tumor Response Evaluation: Of the 25 patients who had been evaluated for at least 2 imaging images, the identified objective remission rate (ORR) was 24% and the disease control rate (DCR) was 84%.
some patients have been treated for up to 11 months and continue to be treated.
safety: combination therapy is well tolerated and there are no serious adverse events associated with treatment.
most treatment-related adverse events (TRAE) are at level 1-2 and the incidence of TraE at Level 3 is 12.9%, of which only 1 patient (3.2%) Level 3 hypertension occurred, with only 1 patient (3.2%) Treatment is discontinued due to adverse events associated with treatment.
so far, insight database shows that Paanpri monotogensis has initiated six clinical trials in the country, including three first-line therapies: combination chemotherapy first-line treatment of non-small cell lung cancer has entered Clinical Phase III, combined chemotherapy first-line treatment of squamous non-small cell lung cancer has entered clinical phase III, and united Anrotinib first-line advanced liver cell cell cancer has entered clinical phase II.
photo source: Insight Database () Chinese the Director of Oncology Medicine at the Civil Liberation Army General Hospital and lead researcher of the study, Professor Jo Shunchang: The current first-line treatment of non-removable liver cell carcinoma patients is mainly sorafenib and the recently approved Levatini, the total survival of Levalinib is similar to sorafenib, but the total survival rate of sorafenib has been reported at 6 months.
PD-1 monoanti-ampliad combined with low-dose anti-tumor angiogenesis drug Anrotinib initially showed encouraging efficacy and good safety in patients with non-removable hepatoblastoma.
disease control rate of DCR is as high as 84%, with a total survival rate of 91.6% over 6 months, and the efficacy is significantly improved.
combination therapy is safe and controllable, and has potential safety advantages over similar immuno-combined anti-tumor angiogenesis drugs.
preliminary results of this study suggest that we send ampriated mitatore combined with higher doses of annrotinib, which will have the potential to further improve the clinical efficacy of patients with non-removable hepatocellular carcinoma.
References: s1. Kudo M. et al Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepato carcinoma: a randomised phase 3 non-systy trial the Lancet 2018; 391: P1163-1173 , Finn, RS.et al Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma New England Journal of Medicine 2020; 382: 1894-1905 382.